<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Autosomal dominant polycystic kidney disease (ADPKD): Genetics of the disease and mechanisms of cyst growth</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Autosomal dominant polycystic kidney disease (ADPKD): Genetics of the disease and mechanisms of cyst growth</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Autosomal dominant polycystic kidney disease (ADPKD): Genetics of the disease and mechanisms of cyst growth</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">York Pei, MD, FRCPC, FACP, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Terry Watnick, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald D Perrone, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Benjamin A Raby, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Autosomal dominant polycystic kidney disease (ADPKD) is a common disorder, occurring in approximately 1 in every 400 to 1000 live births [<a href="#rid1">1,2</a>]. It is estimated that less than one-half of affected individuals will be diagnosed during their lifetime since the disease is often clinically silent [<a href="#rid1">1,3</a>].</p><p>The genetics of ADPKD and the mechanisms of cyst growth will be reviewed here. Issues related to the diagnosis of and screening for ADPKD and for autosomal recessive polycystic kidney disease, which is a disease of children, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1678.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD) in adults: Epidemiology, clinical presentation, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6138.html" rel="external">"Autosomal recessive polycystic kidney disease in children"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>Mutations in one of two genes, <em>PKD1</em> or <em>PKD2</em>, account for most cases of ADPKD. The two disease loci segregate independently since they reside on separate chromosomes. The <em>PKD1</em> gene is located on chromosome 16p13.3, and the <em>PKD2</em> gene is located on chromosome 4q21. (See <a class="local">'PKD1 and PKD2 genes'</a> below.)</p><p>The estimated minimal prevalence of ADPKD is approximately 1 per 1000 based upon pathogenic protein-truncating <em>PKD1</em> and <em>PKD2</em> mutations identified by population-based whole genome and exome sequencing. The disease prevalence is estimated to be higher if nontruncating but likely pathogenic variants are included [<a href="#rid3">3</a>].  </p><p>There is evidence that the <em>PKD1</em> and <em>PKD2</em> disease loci can have synergistic effects. A family has been reported with bilineal inheritance, in which one parent had a mutation in <em>PKD1 </em>and the other parent had a mutation in <em>PKD2</em> [<a href="#rid4">4</a>]. The two family members with both mutations progressed to end-stage kidney disease (ESKD) approximately 20 years earlier than family members with only one <em>PKD1</em> or <em>PKD2</em> mutation.</p><p>A few families with ADPKD are not linked to either locus [<a href="#rid5">5-7</a>].</p><p>A third ADPKD gene has not been identified. A study that re-evaluated five such families has shown that the absence of linkage was due to misdiagnosis, DNA contamination, and genotype errors and did not support the presence of a third gene [<a href="#rid8">8</a>]. On the other hand, at least seven genes (ie, <em>ALG5</em>, <em>ALG8</em>, <em>ALG9</em>, <em>SEC 61B</em>, <em>SEC63</em>, <em>GANAB</em>, and <em>PRKCSH</em>) have been identified for autosomal dominant polycystic liver disease (ADPLD), which can be associated with very mild to moderate kidney phenotype (ie, a few to multiple but not innumerable kidney cysts) [<a href="#rid9">9-13</a>]. Additionally, <em>DNAJB11</em> and <em>IFT140</em> mutations can also be a rare cause of atypical ADPKD [<a href="#rid14">14,15</a>]. Some patients with <em>DNAJB11</em> mutations have CKD and cystic kidney atrophy rather than enlargement [<a href="#rid14">14</a>]. Patients harboring mutations in one of these genes may be misdiagnosed with ADPKD but are generally not at risk for progressive chronic kidney disease. (See <a class="local">'PLD gene products modify polycystin-1 dose'</a> below.)</p><p class="headingAnchor" id="H249734786"><span class="h2">Prevalence of PKD1 and PKD2</span><span class="headingEndMark"> — </span>Initial studies found that mutations in <em>PKD1</em> were responsible for 96 percent of cases of ADPKD [<a href="#rid16">16,17</a>]. Subsequent reports found a lower incidence of <em>PKD1</em> of 86 percent in a study from Europe [<a href="#rid18">18</a>] and 74 percent in a study from Canada [<a href="#rid19">19</a>].</p><p>A possible contributing factor to these findings is that patients with <em>PKD2</em> have a <strong>later onset</strong> of clinically apparent disease than patients with <em>PKD1</em>, which can lead to delayed diagnosis. Macroscopic cysts occur later in <em>PKD2</em>, as do clinical findings such as hypertension, kidney pain, and development of ESKD. (See  <a class="medical medical_review" href="/z/d/html/1678.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD) in adults: Epidemiology, clinical presentation, and diagnosis", section on 'Epidemiology'</a>.)</p><p>The following findings are illustrative:</p><p class="bulletIndent1"><span class="glyph">●</span>In a report from the European <em>PKD1</em>-<em>PKD2</em> study group that included 333 patients with <em>PKD1</em> and 291 with <em>PKD2</em>, the patients with <em>PKD2</em> were less likely to have hypertension (odds ratio [OR] 0.25) or gross (macroscopic) hematuria and progressed to ESKD at an older age (median 74 versus 54 years) [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study from Canada that included 484 patients, the presence of at least one affected family member with ESKD at age ≤55 years was highly predictive of a <em>PKD1</em> mutation [<a href="#rid19">19</a>]. In contrast, maintenance of sufficient kidney function to not require dialysis or the development of ESKD until after 70 years of age in at least one affected family member was highly predictive of a <em>PKD2</em> mutation. The positive predictive value was 100 percent for both findings with a sensitivity of 72 to 74 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study performed in the Genkyst cohort conducted mutation analysis on 741 patients from 519 pedigrees in the Brittany region of France. <em>PKD1</em> and <em>PKD2</em> mutations were identified in 75.5 percent and <em>PKD2</em> in 18.3 percent of patients, respectively. The median age of ESKD was 58.1 years in <em>PKD1</em> mutation carriers versus 79.7 years in those individuals with <em>PKD2</em> mutations. The mean age of hypertension diagnosis was approximately 10 years earlier in <em>PKD1</em> compared with <em>PKD2</em> (37 years versus 49 years, respectively) [<a href="#rid21">21</a>].</p><p></p><p class="headingAnchor" id="H164482583"><span class="h2">PKD1 and PKD2 genes</span><span class="headingEndMark"> — </span>The genes for both <em>PKD1</em> and <em>PKD2</em> have been identified. The <em>PKD1</em> gene is located on chromosome 16p13.3 [<a href="#rid16">16,17,22-25</a>], and the <em>PKD2</em> gene is located on chromosome 4q21 [<a href="#rid18">18,25-27</a>]. The gene products, polycystin-1 and polycystin-2, and their function are discussed below. (See <a class="local">'PKD gene products'</a> below.)</p><p>The <em>PKD1</em> gene is both a large and complex gene (46 exons). Exons 1 to 34, which comprise two-thirds of the coding sequence, are highly similar to several nearby genes, making it challenging to perform mutation screening in this "duplicated" region. In contrast, the <em>PKD2</em> gene is much smaller, and mutation screening of this gene is straightforward [<a href="#rid28">28</a>].</p><p>The <em>PKD1</em> gene is adjacent to a disease gene for tuberous sclerosis (<em>TSC2</em>) [<a href="#rid22">22</a>], a disorder that is characterized primarily by renal angiomyolipomas and kidney cysts. Contiguous deletions of both the <em>PKD1</em> and <em>TSC2</em> genes cause a rare but severe form of PKD associated with ESKD that typically occurs in childhood or teenage years [<a href="#rid29">29,30</a>]. (See  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex", section on 'TSC2/PKD1 contiguous gene syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/142618.html" rel="external">"Tuberous sclerosis complex: Genetics and pathogenesis", section on 'Genotype-phenotype correlations'</a>.)</p><p>The availability of protocols for locus-specific amplification of the <em>PKD1</em> gene has enabled comprehensive mutation screening in large cohorts of patients with ADPKD [<a href="#rid31">31,32</a>]. A large number of mutations have been described in both the <em>PKD1</em> and <em>PKD2</em> genes, with most mutations being unique to single families [<a href="#rid21">21,31</a>]. Most of these mutations are due to nonsense, frameshift, or splice-site alterations that are predicted to be protein truncating and inactivating. The clinical significance of up to one-third of the other <em>PKD1</em> mutations is less clear. Advances in next-generation sequencing technologies have been used for high-throughput mutation screening of both <em>PKD1</em> and <em>PKD2</em>, with a "proof of principle" study showing promising results [<a href="#rid33">33</a>]. The adaptation of this new technology for molecular diagnostics in ADPKD has the potential to facilitate mutation screening at reduced costs.</p><p>There is variability in the kidney manifestations of ADPKD. Some <em>PKD1</em> missense variants reduce, but do not abolish, <em>PKD1</em> activity and are called "hypomorphic alleles." These alleles are associated with a milder form of ADPKD, similar to <em>PKD2</em> [<a href="#rid21">21,34-36</a>]. On the other hand, the presence of a hypomorphic allele may modify disease severity in rare families with bilineal inheritance of two <em>PKD1</em> mutations (ie, one from each parent), resulting in prenatal PKD in the offspring who carry both <em>PKD1</em> mutations [<a href="#rid37">37</a>]. In addition, within-family variability in ADPKD kidney manifestations suggests a significant contribution from modifier genes, independent of the germline (inherited) mutation [<a href="#rid38">38-41</a>]. Identification of these modifiers is expected to be difficult since multiple genes are likely to be involved, each with only a modest effect size [<a href="#rid41">41</a>].</p><p>The role of genetic factors in the rate of progression of ADPKD is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1678.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD) in adults: Epidemiology, clinical presentation, and diagnosis", section on 'Epidemiology'</a>.)</p><p>Some patients with PKD do not have detectable mutations in either <em>PKD1</em> or <em>PKD2</em> genes; some of these patients may have somatic mosaicism. Patients with mosaicism have two genetically different populations of cells due to a de novo mutation occurring during early embryonic development [<a href="#rid42">42,43</a>]. This additional de novo mutation, affecting a subset of cells, results in the dilution of the mutant gene dose. Cells collected from these patients produce a low signal-to-noise ratio on Sanger sequencing, potentially leading to false negative results for <em>PKD1</em> or <em>PKD2</em> gene mutations [<a href="#rid43">43</a>]. In one study, approximately 15 percent of patients suspected to have ADPKD did not have a mutation detected by Sanger sequencing in either the <em>PKD</em>1 or <em>PKD</em>2 genes [<a href="#rid36">36</a>]. Most of these patients did not have a family history of ADPKD and they exhibited atypical findings on imaging [<a href="#rid42">42</a>]. In another study, patients from 20 such families (without detectable <em>PKD1</em> or <em>PKD2</em> mutations) were diagnosed as having somatic mosaicism using next-generation sequencing with high read-depth [<a href="#rid44">44</a>].      </p><p class="headingAnchor" id="H3"><span class="h2">PKD gene products</span><span class="headingEndMark"> — </span>The <em>PKD1</em> and <em>PKD2</em> genes encode proteins called polycystin-1 and polycystin-2, respectively [<a href="#rid22">22-25,27,28,45</a>]. </p><p><em>PKD1</em> is a large gene (46 exons), encoding polycystin-1, which is more than 4000 amino acids in length [<a href="#rid22">22-24,28</a>]. Polycystin-1 is predicted to contain 11 transmembrane domains, a short intracellular C-terminus, and a large extracellular region with a novel combination of motifs [<a href="#rid22">22,23</a>], suggesting that it participates in adhesive cell-cell or cell-matrix interactions. The protein undergoes a variety of cleavage events, including at a juxtamembrane G protein-coupled receptor (GPCR) proteolytic site (GPS) motif. This cleavage does not require an exogenous protease and is therefore said to occur via "cis-autoproteolysis." Cleavage at the GPS site results in two fragments that remain noncovalently associated. This cleavage event is required to maintain tubular morphology since a knock-in mouse model with a mutation at the GPS site results in ADPKD with cysts primarily affecting the collecting duct [<a href="#rid46">46,47</a>]. In addition, mechanical stimuli result in the intracellular release of the cytoplasmic tail [<a href="#rid48">48,49</a>]. This protein fragment is then translocated into the nuclei to activate transcriptional pathways such as activating protein-1 (AP-1) [<a href="#rid48">48,50,51</a>]. One report suggests that the polycystin-1 cytoplasmic tail also translocates to the mitochondrial matrix where it could regulate mitochondrial structure and function [<a href="#rid52">52</a>].</p><p>The <em>PKD2</em> gene is much smaller than <em>PKD1</em> (15 exons) and encodes polycystin-2, which is less than 1000 amino acids in length [<a href="#rid28">28</a>]. Polycystin-2 is a calcium-permeable channel with six transmembrane (TM) spanning elements that is a member of the transient receptor potential (TRP) family of nonselective cation channels [<a href="#rid45">45</a>]. Polycystin-2 also has homology to the last six transmembrane domains of polycystin-1 [<a href="#rid27">27</a>]. Four polycystin-2 channels form a tetrameric structure with a voltage-sensing domain, a pore loop between TM5 and TM6, and a novel "TOP" domain comprised of the large extracellular loop between TM1 and TM2. [<a href="#rid53">53,54</a>]. The TOP domain is postulated to be critical for channel assembly and/or function since it is a hotspot for missense disease-causing variants [<a href="#rid54">54</a>]. Polycystin-2 interacts with Polycystin 1 via their C-termini and possibly TOP domains [<a href="#rid53">53-55</a>].  </p><p class="headingAnchor" id="H3628802249"><span class="h2">PLD gene products modify polycystin-1 dose</span><span class="headingEndMark"> — </span>At least five genes have been identified to cause ADPLD with a mild kidney phenotype, including <em>ALG8</em>, <em>SEC 61B</em>, <em>SEC63</em>, <em>GANAB</em>, and <em>PRKCSH</em>, which respectively encode alpha-1,3-glucosyltransferase, SEC61-beta, SEC63p, and alpha- and beta-catalytic subunits of glucosidase II [<a href="#rid11">11,12</a>]. The proteins encoded by these genes all function in the endoplasmic reticulum (ER) posttranslational protein biogenesis pathway, and mutations in any of these genes have been shown to reduce the maturation and cell membrane expression of polycystin-1. (See <a class="local">'Polycystin function'</a> below.)</p><p class="headingAnchor" id="H23546035"><span class="h2">Polycystin localization</span><span class="headingEndMark"> — </span>The sites of localization of polycystin-1 and polycystin-2 have been controversial due to issues of antibody specificity [<a href="#rid24">24,56,57</a>]. The following features are characteristic of both proteins:</p><p class="bulletIndent1"><span class="glyph">●</span>Polycystins are localized in renal tubular epithelia, hepatic bile ductules, and pancreatic ducts, all of which are sites of cyst formation in ADPKD. Polycystins also are expressed in endothelial and vascular smooth muscle cells and are found in major blood vessels such as the aorta, aortic branches, and the Circle of Willis [<a href="#rid58">58-60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polycystins are overexpressed in most, but not all, cyst epithelial cells in kidneys from patients with ADPKD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polycystins are integral membrane proteins that are found primarily in plasma membranes but also in the primary cilium. The primary cilium is an organelle that arises from the surface of most cells and acts as cell sensors that facilitate the interactions between the cell and its environment [<a href="#rid61">61</a>].</p><p></p><p>Several studies have shown that there are various cellular pools of polycystin-1 and polycystin-2. Polycystin-1 and polycystin-2 interact in the endoplasmic reticulum, and this interaction is required for the mature polycystin complex to reach the cell surface, including the cilium. Similarly, polycystin-1 cleavage is necessary for ciliary localization of both polycystin-1 and polycystin-2 [<a href="#rid62">62-64</a>].</p><p class="headingAnchor" id="H23546596"><span class="h2">Polycystin function</span><span class="headingEndMark"> — </span>Studies analyzing the proposed protein structure of the <em>PKD1</em> gene product, <strong>polycystin-1</strong>, and its membrane localization in cells in culture suggest that it is involved in adhesive protein-protein, cell-cell, and/or cell-matrix interactions [<a href="#rid23">23,56</a>]. As an example, polycystin-1 localizes to the lateral membranes of cells, making cell-cell contact in vitro [<a href="#rid56">56</a>]. In addition, polycystin-1 may exist in a complex with E-cadherin and the catenins, two proteins that are involved in cell adhesion [<a href="#rid57">57</a>].</p><p>Thus, an abnormality in polycystin-1 may impair cell-cell and cell-matrix interactions, leading to abnormal epithelial cell differentiation and the various phenotypic expressions of ADPKD. The demonstration of impaired in vitro tubulogenesis in cyst-derived cells from ADPKD kidneys is compatible with this hypothesis [<a href="#rid65">65</a>].</p><p>A ligand for the polycystin complex has not been identified [<a href="#rid25">25</a>]. However, it has been proposed that the cleaved N-terminus of polycystin-1 can act as a soluble ligand that activates the heteromeric polycystin-1/polycystin-2 complex [<a href="#rid66">66</a>]. </p><p>The <em>PKD2</em> gene product, <strong>polycystin-2</strong>, is thought to be involved in calcium signaling [<a href="#rid25">25,45</a>]. There is strong evidence that polycystin-2 functions as a calcium-regulated nonselective cation channel:</p><p class="bulletIndent1"><span class="glyph">●</span>Expression studies using polycystin-L (PKDL), a protein with high homology to polycystin-2 and TRP cation channels, show that PKDL functions as a cation channel that is permeable to calcium, sodium, and potassium [<a href="#rid67">67</a>]. In the kidney, it is predominantly localized to principal cells in the inner medullary collecting ducts [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interaction between polycystin-1 and polycystin-2 creates a new, calcium-permeable, nonselective cation current, although the exact role for polycystin-1 is unclear [<a href="#rid45">45</a>]. Such activity is not observed with either protein alone or with disease-associated mutant proteins incapable of heterodimerization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Direct ciliary patch clamp recordings from cultured cells lacking polycystin-2 demonstrated a ciliary current that is dependent on PKD2<em> </em>[<a href="#rid69">69</a>]. This channel appears to have high conductance with permeability to K<sup>+</sup>&gt;Ca<sup>2+</sup>&gt;Na<sup>+</sup>. This is in keeping with the idea that polycystin-2 is a nonselective cation channel.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cryogenic electron microscopy studies of the six polycystin-2 transmembrane domains (S1-S6) in lipid nanodiscs show that in the absence of polycystin-1, the polycystin-2 channel has a tetrameric structure that forms the channel pore [<a href="#rid53">53</a>]. This shortened polycystin-2 channel conducts Na<sup>+ </sup>and K<sup>+</sup> but has a lower permeability and smaller single-channel conductance to Ca<sup>2+</sup>. Polycystin-2 channels have a unique structural feature, called the Polycystin or tetragonal opening for polycystins (TOP) domain, which is a large extracellular loop between S1 and S2 [<a href="#rid53">53,54</a>]. These domains work with other domains forming a lid-like structure that may open the channel pore in response to voltage-dependent conformational changes. Missense mutations in the TOP domain de-stabilize the channel structure and impair channel opening without altering the localization of cilia [<a href="#rid70">70</a>]. </p><p></p><p>Since the clinical features of ADPKD1 and ADPKD2 are identical, it has been suggested that polycystin-1 and polycystin-2 interact in a common signaling pathway(s) [<a href="#rid25">25,28,45</a>]. Several lines of evidence provide support for this hypothesis:</p><p class="bulletIndent1"><span class="glyph">●</span>Polycystin-1 and polycystin-2 are expressed in similar cellular and subcellular locations, although the overlap is not complete [<a href="#rid24">24,56,57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polycystin-1 appears to activate the JAK-STAT pathway, thereby inducing cell cycle arrest [<a href="#rid71">71</a>]. Polcystin-2 functions as an essential cofactor for this process. Activation of the pathway is prevented by mutations that disrupt the interaction between polycystin-1 and polycystin-2.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polycystin-1 and polycystin-2 interact via their carboxy terminal coiled domains and TOP domains [<a href="#rid53">53-55</a>]. There are naturally occurring pathogenic mutations in the coiled domains that disrupt this interaction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both polycystins appear to regulate G protein signaling [<a href="#rid72">72</a>]. The carboxy terminal end of polycystin-1 can bind heterotrimeric G proteins, while polycystin-2 interacts with polycystin-1 to antagonize signaling.</p><p></p><p>The precise function of polycystin-1/polycystin-2 heteromers are unclear. Cryogenic electron microscopy studies of shortened polycystin protein fragments suggest heteromer assembly with a 1:3 polycystin-1/polycystin-2 ratio [<a href="#rid73">73</a>]. In this structure, the last six transmembrane domains of polycystin-1 (those with homology to polycystin-2) interdigitate with polycystin-2 to form a structure similar to other TRP-like channels, including the polycystin-2 homomer. Whether this heteromeric channel is functional, however, remains a question because the inclusion of polycystin-1 appears to disrupt the pore structure [<a href="#rid73">73</a>]. </p><p class="headingAnchor" id="H1782919160"><span class="h2">Genome editing of PKD1 and PKD2</span><span class="headingEndMark"> — </span>Genome editing technologies have provided the possibility of future therapeutic interventions to correct the primary defect of ADPKD. Genetic reactivation of <em>PKD1</em> or <em>PKD2</em> in adult mouse models of ADPKD resulted in reversal of ADPKD even with moderately severe disease. These experiments demonstrated extensive plasticity of the kidneys in tissue repair and remodeling [<a href="#rid74">74</a>]. </p><p class="headingAnchor" id="H5"><span class="h1">MECHANISM OF CYST FORMATION AND GROWTH</span><span class="headingEndMark"> — </span>The underlying mechanisms by which cysts form in ADPKD are not fully understood [<a href="#rid50">50,75</a>]. A number of theories have been proposed, including weakening of tubular basement membranes and intratubular obstruction from hyperplastic cells. However, there has been little evidence to support these hypotheses. Furthermore, the observation that human PKD cells, but not normal renal epithelial cells, can form cysts when grown in culture suggests a genetic defect that directly promotes cyst formation [<a href="#rid76">76,77</a>].</p><p>Kidney cysts in ADPKD are derived from different nephron segments, and the epithelial cells lining the cysts appear to retain their transport functions [<a href="#rid75">75,78</a>]. Sodium concentrations vary within different cysts, generally being &lt;60 mEq/L (low-sodium cysts) or &gt;75 mEq/L (high-sodium cysts) [<a href="#rid79">79</a>]. It has been proposed that cysts with high fluid sodium derive from the proximal tubule (particularly in cysts with a sodium concentration similar to that of plasma), while cysts with low fluid sodium derive from the distal nephron (the site at which a low urine sodium concentration is normally achieved). However, careful histological examination has been unable to confirm these relationships since there is a continuum of cyst sodium concentrations, not just high or low values [<a href="#rid79">79</a>]. Fluid secretion in the cysts may be mediated in part by the cystic fibrosis transmembrane conductance regulator (CFTR). (See <a class="local">'Abnormal fluid secretion'</a> below.)</p><p>Early cysts begin as dilatations of intact tubules that are in contact with the nephron and fill by glomerular filtration [<a href="#rid27">27,75</a>]. In contrast, enlarging cysts lose their connection to functioning nephrons as they reach a size of more than 2 to 3 mm. Cyst growth in this setting results from secretion of fluid into the cysts (not glomerular filtration) and is associated with hyperplasia of the cyst epithelium that may reflect underlying maturational arrest [<a href="#rid75">75</a>].</p><p>Human PKD cyst fluid, via an undefined mechanism, promotes additional fluid secretion by a lipid secretagogue [<a href="#rid80">80</a>] and cyst formation when added to renal tubular cells in culture [<a href="#rid76">76</a>]. The rate of increase in total kidney volume was evaluated in a clinical study in which 232 patients with ADPKD and no azotemia were followed for three years with serial magnetic resonance imaging (MRI) studies used to measure the rates of change in total kidney and cyst volume [<a href="#rid81">81</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Total kidney volume was 1060 mL at baseline and increased at a mean rate of 204 mL (5.3 percent) at three years. The mean increase was greater with <em>PKD1</em> than <em>PKD2</em> mutations (245 versus 136 mL).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Total cyst volume increased by a mean of 218 mL at three years and therefore accounted for <strong>all</strong> of the increase in total kidney volume.</p><p></p><p>Higher baseline total kidney volume was associated with a more rapid decrease in kidney function. A baseline total kidney volume &gt;1500 mL was present in 135 patients and was associated with a mean decline in glomerular filtration rate (GFR) of 4.3 mL/min per year.</p><p class="headingAnchor" id="H17678992"><span class="h2">Focal cyst formation and the 'second hit' hypothesis</span><span class="headingEndMark"> — </span>A notable feature of ADPKD is variable phenotypic disease expression. Even though the germline (inherited) genetic defect is present in all cells, cysts form in &lt;10 percent of tubules, and, within tubules, cystic dilatation is focal [<a href="#rid25">25,28,75</a>]. This observation led to a "second-hit" hypothesis of cystogenesis for both <em>PKD1</em> [<a href="#rid82">82-84</a>] and <em>PKD2</em> [<a href="#rid85">85</a>]. Under the "second hit" hypothesis, cysts form in the presence of an inherited <em>PKD1</em> or <em>PKD2</em> mutation only if the remaining normal copy of <em>PKD1</em> or <em>PKD2</em> develops a somatic (acquired not inherited) mutation. Accordingly, studies of individual <em>PKD1</em> kidney cysts, which are monoclonal and derived from a single cell, show both loss of heterozygosity and somatic <em>PKD1</em> mutations [<a href="#rid82">82,83,86</a>].</p><p>This model of cystogenesis has been questioned by some because the original studies detected a low percentage (&lt;30 percent) of <em>PKD1</em> cysts with loss of heterozygosity or somatic <em>PKD1</em> gene mutations [<a href="#rid28">28</a>]. The low detection rate of somatic mutation, however, was likely due to the challenges of performing mutation screening in the duplicated region of <em>PKD1</em> (see <a class="local">'PKD1 and PKD2 genes'</a> above). By comparison, when the entire <em>PKD2</em> gene is screened, approximately 80 percent of kidney and liver cysts from individuals with germline (inherited) <em>PKD2</em> mutations have inactivating <em>PKD2</em> somatic mutations [<a href="#rid85">85,87</a>]. Now, with state of the art sequencing methods, such as whole genome sequencing or next generation sequencing of long range PCR products, somatic mutations of <em>PKD1 </em>or <em>PKD2</em> can be detected in the vast majority (&gt;90 percent) of kidney cysts [<a href="#rid88">88</a>].</p><p>Additional evidence in support of the "second-hit" hypothesis comes from studies in murine models. The following observations are illustrative:</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney and pancreatic cysts develop in mice homozygous for <em>PKD1</em> or <em>PKD2</em> null (lacks molecular function) mutations, but do not occur in heterozygotes [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An unstable <em>PKD2</em> allele was designed to undergo random homologous-recombination, which results in a null allele that can occur in cells after birth [<a href="#rid89">89</a>]. This mimics the ongoing accumulation of somatic (acquired not inherited) mutations that is postulated to occur in human ADPKD. When this unstable allele was combined with a germline <em>PKD2</em> knock-out allele, mice developed kidney cystic disease, resulting in kidney failure and early death.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mutant mice with aberrant mRNA splicing that significantly reduces the level of functional polycystin-1 develop kidney cysts, which is consistent with the hypothesis that cyst formation can be triggered by polycystin levels below a critical threshold [<a href="#rid90">90,91</a>].</p><p></p><p>The above findings, along with reports of cystic disease in patients with homozygous hypomorphic (reduced level of activity) <em>PKD1</em> mutations or with a heterozygous hypomorphic <em>PKD1</em> mutation associated with a second inactivating <em>PKD1</em> mutation, suggest a "threshold mechanism of cystogenesis" model of disease [<a href="#rid25">25,92</a>]. As an example, a dose of functional polycystin that falls below a critical threshold (approximately 10 to 30 percent of normal) within a tubular epithelial cell may be sufficient to initiate cyst formation. It has been proposed that falling below this threshold leads to abnormal fluid secretion, dysregulated cell proliferation, and apoptosis, which promote cyst growth via multiple signaling pathways [<a href="#rid25">25,75,77,91,93,94</a>].</p><p>The time at which the <em>PKD1</em> gene is inactivated is another factor that may modify kidney disease severity, which suggests the existence of a developmental switch. In a murine model, inactivation of the <em>PKD1</em> gene prior to 13 days after birth, while the kidney is still developing, resulted in severe cystic disease within three weeks. In contrast, inactivation of the gene after 14 days of age resulted in a more indolent course, with cyst development after five months [<a href="#rid95">95</a>]. Kidney cystic disease in the late induction model can be accelerated by acute kidney injury or tubular calcium oxalate crystal deposition (also called the "third-hit model") [<a href="#rid96">96-98</a>]. These observations suggest that additional factors such as the "on and off" states of certain cell-signaling pathways are needed for kidney cyst growth.</p><p class="headingAnchor" id="H6"><span class="h2">Abnormal fluid secretion</span><span class="headingEndMark"> — </span>Increased fluid secretion into cysts, possibly mediated by the CFTR, appears to play a role in cyst growth. Fluid accumulation within ADPKD cysts is thought to be driven primarily by 3′,5′-cyclic adenosine monophosphate (cAMP)-dependent chloride secretion [<a href="#rid99">99</a>]. One hypothesis is that chloride transport across the apical membrane occurs via the CFTR. CFTR has the appropriate characteristics since it functions as a cAMP-dependent chloride channel and has been localized to the apical membranes of ADPKD cyst lining cells. Therefore, CFTR has been postulated to contribute to cyst growth [<a href="#rid80">80,100,101</a>]. (See <a class="local">'Role of cyclic AMP and intracellular calcium'</a> below.)</p><p>Suggestive evidence supporting an important pathogenic role for CFTR is provided by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Case reports of a few families with ADPKD and cystic fibrosis reported that individuals with both ADPKD and cystic fibrosis gene mutations may have less severe cystic disease in the kidney and liver compared with family members with ADPKD but without cystic fibrosis [<a href="#rid102">102</a>]. (See  <a class="medical medical_review" href="/z/d/html/1677.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unlike normal renal epithelial cells, in vitro growth of ADPKD cells, as well as enlargement of associated cysts, is markedly stimulated by the addition of cAMP to the culture medium [<a href="#rid103">103</a>]. As mentioned above, CFTR functions as a cAMP-dependent chloride channel.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Small molecule inhibitors of CFTR slow cyst expansion in both cell culture and mouse models of PKD [<a href="#rid104">104</a>].</p><p></p><p>These findings support a pathogenic role of epithelial chloride secretion in the generation and maintenance of fluid-filled cysts in ADPKD and provide novel targets for potential therapeutic intervention.</p><p class="headingAnchor" id="H7"><span class="h2">Role of cyclic AMP and intracellular calcium</span><span class="headingEndMark"> — </span>Derangements in cAMP related to decreased intracellular calcium signaling may underlie the development of cysts via increased fluid secretion and cell proliferation [<a href="#rid105">105-108</a>]. As noted in the preceding section, the CFTR functions as a cAMP-dependent chloride channel.</p><p>Strategies that target cAMP signaling and/or calcium homeostasis have been studied in rodent models of PKD with the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Dual deletion of <em>PKD1</em> and adenylate cyclase 6 in principal cells of the collecting duct markedly decreased cystogenesis, improved kidney function, and increased survival. Inhibitors of specific adenylate cyclase isoforms are not available, but this proof-of-concept study is consistent with other data showing that decreasing levels of cAMP are protective in ADPKD [<a href="#rid109">109</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The administration of a vasopressin V2 receptor antagonist prevents kidney enlargement and inhibits cystogenesis by decreasing kidney cAMP levels [<a href="#rid110">110</a>]. This approach has been validated in two large, randomized, control trials to provide the first mechanism-based therapy for patients with ADPKD [<a href="#rid111">111,112</a>]. (See  <a class="medical medical_review" href="/z/d/html/1677.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Treatment", section on 'Tolvaptan'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Calcium channel blockers, such as <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, increase PKD progression in a rat model of PKD that is not caused by mutations in either <em>PKD1</em> or <em>PKD2</em> [<a href="#rid113">113</a>].</p><p></p><p class="headingAnchor" id="H29439722"><span class="h2">Role of mammalian (mechanistic) target of rapamycin (mTOR)</span><span class="headingEndMark"> — </span>Activation of the mTOR protein may contribute to cyst growth in ADPKD [<a href="#rid114">114</a>]. In contrast, inhibition of mTOR with rapamycin (<a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>) preserved kidney function and inhibited epithelial cell proliferation and fibrosis in a mouse model of ADPKD in which the <em>PKD1</em> gene was conditionally deleted [<a href="#rid115">115</a>].</p><p>Clinical trials have suggested that mTOR inhibitors may slow the increase in liver and kidney volumes in patients with ADPKD, but do not appear to preserve kidney function, at least over the short term. The limited efficacy may be due in part to low tissue concentrations. In addition, toxicity is a major issue that may limit the therapeutic efficacy of these drugs. </p><p>More selective rapamycin delivery that preferentially targets cystic tissues might increase therapeutic efficacy and minimize rapamycin toxicity. One approach that has been evaluated is the administration of folate-conjugated rapamycin [<a href="#rid116">116</a>]. The folate receptor is highly expressed in cyst-lining cells in both ADPKD and mouse models. The folate conjugate is cleaved intracellularly to reconstitute the active drug. In a mouse model of PKD, folate-conjugated rapamycin slowed the growth of kidney cysts and preserved kidney function [<a href="#rid116">116</a>]. mTOR activity was reduced in kidneys, but not other organs, which may minimize rapamycin toxicity. </p><p class="headingAnchor" id="H1409668"><span class="h2">Impaired glucose metabolism and possible role for metformin</span><span class="headingEndMark"> — </span>Altered glucose metabolism may play an important role in kidney cyst formation. In a knock-out mouse model of <em>PKD1</em> and in kidneys from humans with ADPKD, there is a preferential shift of energy metabolism to aerobic glycolysis in renal cells [<a href="#rid117">117</a>]. Targeting this pathway in the knock-out mouse by the administration of a nonmetabolized glucose analog, 2-deoxyglucose, led to a reduction in the severity of the kidney cystic disease by modulating both mTOR and adenosine monophosphate-activated protein kinase (AMPK) (see <a class="local">'Role of mammalian (mechanistic) target of rapamycin (mTOR)'</a> above). </p><p><a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> is a modulator of glucose metabolism that has been proposed as a treatment for ADPKD. Metformin is an indirect pharmacologic activator of AMPK, which downregulates mTOR and CFTR, proteins that drive cyst expansion through proliferative and secretory effects. Metformin has been shown to slow kidney cyst growth in mouse and miniature pig models of ADPKD, at least in part by inhibiting both the mTOR and CFTR pathways [<a href="#rid118">118-120</a>]. Similarly, <a class="drug drug_general" data-topicid="9876" href="/z/d/drug information/9876.html" rel="external">salsalate</a>, a prodrug dimer of salicylate, which is a direct AMPK activator, has also been shown to slow cystic disease progression in an adult-onset Pkd1 conditional mouse model [<a href="#rid121">121</a>]. These findings provide the rationale for repurposing AMPK activators for clinical testing in patients with ADPKD. Two phase 2 trials of metformin in patients with ADPKD and eGFR &gt;50 have shown that the agent is safe and tolerable [<a href="#rid122">122,123</a>]. Larger trials will be necessary to determine efficacy.</p><p>Dietary interventions that affect glucose metabolism may also hold promise as a means of slowing cyst growth. Dietary caloric restriction (10 to 40 percent) in Pkd1<sup>RC/RC</sup> mice (mice homozygous for a missense <em>PKD1</em> mutation that affects protein trafficking) beginning at six weeks of age for six months or at 5.5 months of age for three months both demonstrated a dose-dependent reduction in the kidney cystic disease severity by suppressing the mTOR pathway by activating AMPK signaling [<a href="#rid124">124,125</a>]. In addition, experimental intermittent fasting without caloric restriction and ketogenic diet may also be beneficial [<a href="#rid126">126</a>].</p><p class="headingAnchor" id="H17583367"><span class="h2">Role of JAK-STAT signaling</span><span class="headingEndMark"> — </span>STAT6, which is activated by the cytokines interleukin (IL)-4 and IL-13, may be a therapeutic target in ADPKD. Studies in mutant animal models have shown that not only is STAT6 activated in cyst lining epithelia, but cyst fluid contains elevated levels of IL-13, suggesting that there may be a positive feedback loop involving autocrine signaling by IL-13. Interestingly, microdissected cysts from ADPKD kidneys also had elevated expression of IL-13 receptor isoforms. Treatment of a nonorthologous mouse model of PKD with <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>, which has several molecular targets including STAT6, ameliorated cystic kidney disease [<a href="#rid127">127</a>].</p><p class="headingAnchor" id="H17679141"><span class="h2">Angiogenesis</span><span class="headingEndMark"> — </span>Angiogenesis may play a role in cyst growth and disease progression in ADPKD [<a href="#rid128">128,129</a>]. This is supported by the observation in kidneys of patients with ADPKD that a rich network of capillary neovascularization is embedded within the walls of macrocysts and that kidney cysts display a profile of gene and protein signatures indicative of active angiogenesis [<a href="#rid94">94,129,130</a>]. It is unclear if antiangiogenic interventions have a therapeutic role in ADPKD.</p><p class="headingAnchor" id="H9"><span class="h2">Abnormal cilia function</span><span class="headingEndMark"> — </span>Virtually all of the protein products that have been implicated in a wide array of human and animal cystic kidney diseases localize to the primary cilia of renal tubular cells [<a href="#rid131">131,132</a>]. These protein products include polycystin-1 and polycystin-2 in ADPKD, fibrocystin in autosomal recessive polycystic kidney disease, and the nephronophthisis gene products. (See <a class="local">'PKD gene products'</a> above and  <a class="medical medical_review" href="/z/d/html/6138.html" rel="external">"Autosomal recessive polycystic kidney disease in children", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/z/d/html/6136.html" rel="external">"Genetics and pathogenesis of nephronophthisis", section on 'Genetics'</a>.)</p><p>There are many potential ways impaired function of primary cilia may impact cyst formation in ADPKD. One hypothesis is that loss of primary cilia can induce kidney cyst formation by disrupting the normal orientation of tubular epithelial cells, which is called planar cell polarity [<a href="#rid133">133,134</a>]. Instead of maintaining a normal elongated tubular geometry, defective planar cell polarity signaling results in saccular dilatation of tubules, which eventually evolves into a cyst.</p><p>Although both polycystin-1 and polycystin-2 are located in the primary cilia, the mechanism(s) by which defective polycystins may affect cilia function and lead to cyst formation in ADPKD remains unclear. One possibility is that the inability to sense fluid flow by the defective ciliary polycystin complex may result in reduced intracellular calcium flux, which then stimulates cAMP signaling, causing dysregulated cyst growth [<a href="#rid25">25,132,135,136</a>]. One study calls this hypothesis into question since depletion of polycystin-2 in the cilia of retinal pigment epithelial cells does not alter ciliary calcium currents measured by direct patch clamp methods. However, depletion of polycystin homologs, PKD2L1 and PKD1 L1, which interact with one another, appear to mediate ciliary calcium currents [<a href="#rid137">137</a>] (see <a class="local">'PKD gene products'</a> above). One line of evidence suggesting that polycystins may act as ciliary sensors comes from the finding that <em>PKD2</em> mutant mice have situs inversus, a phenotype that is classically associated with ciliary function in the embryonic node [<a href="#rid138">138</a>]. </p><p>The connection between cilia, growth, and PKD is complex. Mutations in genes involved in ciliary assembly such as TG737 and Kif3a result in PKD in mice. Studies using a combination of mutations in mice have shown that deleting cilia unexpectedly suppresses cyst growth. One explanation is that cyst growth is dependent on intact cilia. When cilia are deleted in the absence of polycystins, growth is reduced [<a href="#rid139">139</a>]. Insight into the connection between abnormal cilia function and dysregulated cell growth may also be provided by observations that cilia are connected to centrosomal structures [<a href="#rid140">140</a>]. The centrosome, in turn, may have a significant role in the regulation of cell-cycle progression and control, with abnormalities in the cilia/centrosome apparatus possibly resulting in abnormal cellular proliferation. Additional support for this is provided by the observation that most of the proteins associated with the Bardet-Biedl syndrome (which has cystic/dysplasia) also localize to centrosomal structures [<a href="#rid141">141,142</a>].</p><p class="headingAnchor" id="H29268783"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16253.html" rel="external">"Patient education: Polycystic kidney disease (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4419.html" rel="external">"Patient education: Polycystic kidney disease (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics of autosomal dominant polycystic kidney disease</strong> – Autosomal dominant polycystic kidney disease (ADPKD) occurs in approximately 1 in every 400 to 1000 live births. Fewer than one-half of cases are diagnosed during the patient's lifetime as the disease is frequently clinically silent. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PKD1 and PKD2 mutations</strong> – Multiple causative genetic defects have been described, most of which are within the <em>PKD1</em> locus on chromosome 16, resulting in ADPKD1 disease. A smaller number of patients have a defect in the <em>PKD2</em> locus on chromosome 4 (resulting in ADPKD2 disease), and a few families have neither <em>PKD1</em> nor <em>PKD2</em> mutations. (See <a class="local">'Prevalence of PKD1 and PKD2'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PKD gene products</strong> – <em>PKD1</em> and <em>PKD2</em> encode proteins called polycystin-1 and polycystin-2, respectively. (See <a class="local">'PKD1 and PKD2 genes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Polycystin localization, function</strong>, <strong>and interaction</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Polycystin-1</strong> – Polycystin-1 is a membrane protein localized at sites of cyst formation, including renal tubular epithelia, hepatic bile ductules, and pancreatic ducts. Possible roles of polycystin-1 include the regulation of protein-protein, cell-cell, and cell-matrix interactions and of intracellular signaling pathways involved in the regulation of cell proliferation and survival. (See <a class="local">'Polycystin localization'</a> above and <a class="local">'Polycystin function'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Polycystin-2 </strong>–<strong> </strong>Polycystin-2 is expressed in the distal tubules, collecting duct, and thick ascending limb and is involved in cell calcium signaling. (See <a class="local">'Polycystin localization'</a> above and <a class="local">'Polycystin function'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Interactions between polycystin-1 and polycystin-2</strong> – Polycystin-1 and polycystin-2 also interact in common pathways and function together as an important regulator of calcium influx as a nonselective calcium ion channel. (See <a class="local">'Polycystin function'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of cyst formation and growth</strong> – The mechanism by which cysts form is unclear. Cyst formation may result from multiple aberrant processes including abnormal fluid secretion and cell proliferation and apoptosis. Early cysts begin as dilatations in intact tubules that are in contact with the nephron. However, enlarging cysts lose their connection to functioning nephrons. Cyst growth in this setting results from secretion of fluid into the cysts and is associated with hyperplasia of the cyst epithelium. (See <a class="local">'Mechanism of cyst formation and growth'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>The 'second hit' hypothesis</strong> – In addition to the inheritance of an abnormal <em>PKD1</em> gene, cysts appear to form only when there is a second, acquired somatic loss of the normal haplotype; this is referred to as the second-hit hypothesis. More recent data suggest a "threshold mechanism" whereby functional polycystin levels below a critical threshold (ie, 10 to 30 percent) within a tubular epithelial cell may trigger the cystogenic process. As a result, although the genetic defect is present in all cells, cysts form in &lt;10 percent of tubules, and cystic dilatation is focal within tubules. (See <a class="local">'Focal cyst formation and the 'second hit' hypothesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cyclic AMP and mammalian (mechanistic) target of rapamycin</strong> – Elevations in cyclic adenosine monophosphate (cAMP) related to decreased intracellular calcium signaling may enhance cyst formation by increasing fluid secretion and cell proliferation. Vasopressin V2 receptor antagonists, increases in the intracellular calcium concentration, and calcimimetics all may decrease cyst growth. Aberrant activation of mammalian (mechanistic) target of rapamycin (mTOR) signaling pathway may also enhance kidney cyst growth. (See <a class="local">'Role of cyclic AMP and intracellular calcium'</a> above and <a class="local">'Role of mammalian (mechanistic) target of rapamycin (mTOR)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Angiogenesis – </strong>Angiogenesis may contribute to cyst growth. (See <a class="local">'Angiogenesis'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Abnormal cilia function</strong> – Abnormalities of kidney cilia function may contribute to kidney cyst formation. The potential causes and consequences of cilia dysfunction in ADPKD remain unclear. (See <a class="local">'Abnormal cilia function'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Davies F, Coles GA, Harper PS, et al. Polycystic kidney disease re-evaluated: a population-based study. Q J Med 1991; 79:477.</a></li><li><a class="nounderline abstract_t">Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359:1477.</a></li><li><a class="nounderline abstract_t">Lanktree MB, Haghighi A, Guiard E, et al. Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing. J Am Soc Nephrol 2018; 29:2593.</a></li><li><a class="nounderline abstract_t">Pei Y, Paterson AD, Wang KR, et al. Bilineal disease and trans-heterozygotes in autosomal dominant polycystic kidney disease. Am J Hum Genet 2001; 68:355.</a></li><li><a class="nounderline abstract_t">Daoust MC, Reynolds DM, Bichet DG, Somlo S. Evidence for a third genetic locus for autosomal dominant polycystic kidney disease. Genomics 1995; 25:733.</a></li><li><a class="nounderline abstract_t">de Almeida E, Martins Prata M, de Almeida S, Lavinha J. Long-term follow-up of a family with autosomal dominant polycystic kidney disease type 3. Nephrol Dial Transplant 1999; 14:631.</a></li><li><a class="nounderline abstract_t">Paterson AD, Pei Y. Is there a third gene for autosomal dominant polycystic kidney disease? Kidney Int 1998; 54:1759.</a></li><li><a class="nounderline abstract_t">Paul BM, Consugar MB, Ryan Lee M, et al. Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families. Kidney Int 2014; 85:383.</a></li><li><a class="nounderline abstract_t">Lemoine H, Raud L, Foulquier F, et al. Monoallelic pathogenic ALG5 variants cause atypical polycystic kidney disease and interstitial fibrosis. Am J Hum Genet 2022; 109:1484.</a></li><li><a class="nounderline abstract_t">Fedeles SV, Gallagher AR, Somlo S. Polycystin-1: a master regulator of intersecting cystic pathways. Trends Mol Med 2014; 20:251.</a></li><li><a class="nounderline abstract_t">Porath B, Gainullin VG, Cornec-Le Gall E, et al. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. Am J Hum Genet 2016; 98:1193.</a></li><li><a class="nounderline abstract_t">Besse W, Dong K, Choi J, et al. Isolated polycystic liver disease genes define effectors of polycystin-1 function. J Clin Invest 2017; 127:1772.</a></li><li><a class="nounderline abstract_t">Besse W, Chang AR, Luo JZ, et al. ALG9 Mutation Carriers Develop Kidney and Liver Cysts. J Am Soc Nephrol 2019; 30:2091.</a></li><li><a class="nounderline abstract_t">Cornec-Le Gall E, Olson RJ, Besse W, et al. Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. Am J Hum Genet 2018; 102:832.</a></li><li><a class="nounderline abstract_t">Senum SR, Li YSM, Benson KA, et al. Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. Am J Hum Genet 2022; 109:136.</a></li><li><a class="nounderline abstract_t">Parfrey PS, Bear JC, Morgan J, et al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323:1085.</a></li><li><a class="nounderline abstract_t">Breuning MH, Reeders ST, Brunner H, et al. Improved early diagnosis of adult polycystic kidney disease with flanking DNA markers. Lancet 1987; 2:1359.</a></li><li><a class="nounderline abstract_t">Peters DJ, Spruit L, Saris JJ, et al. Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease. Nat Genet 1993; 5:359.</a></li><li><a class="nounderline abstract_t">Barua M, Cil O, Paterson AD, et al. Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 2009; 20:1833.</a></li><li><a class="nounderline abstract_t">Hateboer N, v Dijk MA, Bogdanova N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353:103.</a></li><li><a class="nounderline abstract_t">Cornec-Le Gall E, Audrézet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 2013; 24:1006.</a></li><li><a class="nounderline abstract_t">The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium. Cell 1994; 77:881.</a></li><li><a class="nounderline abstract_t">Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 1995; 81:289.</a></li><li><a class="nounderline abstract_t">Geng L, Segal Y, Peissel B, et al. Identification and localization of polycystin, the PKD1 gene product. J Clin Invest 1996; 98:2674.</a></li><li><a class="nounderline abstract_t">Gallagher AR, Germino GG, Somlo S. Molecular advances in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010; 17:118.</a></li><li><a class="nounderline abstract_t">Pei Y, He N, Wang K, et al. A spectrum of mutations in the polycystic kidney disease-2 (PKD2) gene from eight Canadian kindreds. J Am Soc Nephrol 1998; 9:1853.</a></li><li><a class="nounderline abstract_t">Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996; 272:1339.</a></li><li><a class="nounderline abstract_t">Ong AC, Harris PC. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int 2005; 67:1234.</a></li><li><a class="nounderline abstract_t">Brook-Carter PT, Peral B, Ward CJ, et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome. Nat Genet 1994; 8:328.</a></li><li><a class="nounderline abstract_t">Sampson JR, Maheshwar MM, Aspinwall R, et al. Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am J Hum Genet 1997; 61:843.</a></li><li><a class="nounderline abstract_t">Rossetti S, Consugar MB, Chapman AB, et al. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2007; 18:2143.</a></li><li><a class="nounderline abstract_t">Garcia-Gonzalez MA, Jones JG, Allen SK, et al. Evaluating the clinical utility of a molecular genetic test for polycystic kidney disease. Mol Genet Metab 2007; 92:160.</a></li><li><a class="nounderline abstract_t">Rossetti S, Hopp K, Sikkink RA, et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol 2012; 23:915.</a></li><li><a class="nounderline abstract_t">Rossetti S, Kubly VJ, Consugar MB, et al. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 2009; 75:848.</a></li><li><a class="nounderline abstract_t">Pei Y, Lan Z, Wang K, et al. A missense mutation in PKD1 attenuates the severity of renal disease. Kidney Int 2012; 81:412.</a></li><li><a class="nounderline abstract_t">Hwang YH, Conklin J, Chan W, et al. Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 2016; 27:1861.</a></li><li><a class="nounderline abstract_t">Audrézet MP, Corbiere C, Lebbah S, et al. Comprehensive PKD1 and PKD2 Mutation Analysis in Prenatal Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 2016; 27:722.</a></li><li><a class="nounderline abstract_t">Persu A, Duyme M, Pirson Y, et al. Comparison between siblings and twins supports a role for modifier genes in ADPKD. Kidney Int 2004; 66:2132.</a></li><li><a class="nounderline abstract_t">Paterson AD, Magistroni R, He N, et al. Progressive loss of renal function is an age-dependent heritable trait in type 1 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2005; 16:755.</a></li><li><a class="nounderline abstract_t">Fain PR, McFann KK, Taylor MR, et al. Modifier genes play a significant role in the phenotypic expression of PKD1. Kidney Int 2005; 67:1256.</a></li><li><a class="nounderline abstract_t">Liu M, Shi S, Senthilnathan S, et al. Genetic variation of DKK3 may modify renal disease severity in ADPKD. J Am Soc Nephrol 2010; 21:1510.</a></li><li><a class="nounderline abstract_t">Iliuta IA, Kalatharan V, Wang K, et al. Polycystic Kidney Disease without an Apparent Family History. J Am Soc Nephrol 2017; 28:2768.</a></li><li><a class="nounderline abstract_t">Devuyst O, Pei Y. Next-generation sequencing for detection of somatic mosaicism in autosomal dominant polycystic kidney disease. Kidney Int 2020; 97:261.</a></li><li><a class="nounderline abstract_t">Hopp K, Cornec-Le Gall E, Senum SR, et al. Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney Int 2020; 97:370.</a></li><li><a class="nounderline abstract_t">Hanaoka K, Qian F, Boletta A, et al. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 2000; 408:990.</a></li><li><a class="nounderline abstract_t">Qian F, Boletta A, Bhunia AK, et al. Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations. Proc Natl Acad Sci U S A 2002; 99:16981.</a></li><li><a class="nounderline abstract_t">Yu S, Hackmann K, Gao J, et al. Essential role of cleavage of Polycystin-1 at G protein-coupled receptor proteolytic site for kidney tubular structure. Proc Natl Acad Sci U S A 2007; 104:18688.</a></li><li><a class="nounderline abstract_t">Chauvet V, Tian X, Husson H, et al. Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J Clin Invest 2004; 114:1433.</a></li><li><a class="nounderline abstract_t">Lal M, Song X, Pluznick JL, et al. Polycystin-1 C-terminal tail associates with beta-catenin and inhibits canonical Wnt signaling. Hum Mol Genet 2008; 17:3105.</a></li><li><a class="nounderline abstract_t">Wilson PD. Polycystic kidney disease. N Engl J Med 2004; 350:151.</a></li><li><a class="nounderline abstract_t">Le NH, van der Wal A, van der Bent P, et al. Increased activity of activator protein-1 transcription factor components ATF2, c-Jun, and c-Fos in human and mouse autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2005; 16:2724.</a></li><li><a class="nounderline abstract_t">Lin CC, Kurashige M, Liu Y, et al. A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed. Sci Rep 2018; 8:2743.</a></li><li><a class="nounderline abstract_t">Shen PS, Yang X, DeCaen PG, et al. The Structure of the Polycystic Kidney Disease Channel PKD2 in Lipid Nanodiscs. Cell 2016; 167:763.</a></li><li><a class="nounderline abstract_t">Grieben M, Pike AC, Shintre CA, et al. Structure of the polycystic kidney disease TRP channel Polycystin-2 (PC2). Nat Struct Mol Biol 2017; 24:114.</a></li><li><a class="nounderline abstract_t">Qian F, Germino FJ, Cai Y, et al. PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 1997; 16:179.</a></li><li><a class="nounderline abstract_t">Ibraghimov-Beskrovnaya O, Dackowski WR, Foggensteiner L, et al. Polycystin: in vitro synthesis, in vivo tissue expression, and subcellular localization identifies a large membrane-associated protein. Proc Natl Acad Sci U S A 1997; 94:6397.</a></li><li><a class="nounderline abstract_t">Huan Y, van Adelsberg J. Polycystin-1, the PKD1 gene product, is in a complex containing E-cadherin and the catenins. J Clin Invest 1999; 104:1459.</a></li><li><a class="nounderline abstract_t">Qian Q, Li M, Cai Y, et al. Analysis of the polycystins in aortic vascular smooth muscle cells. J Am Soc Nephrol 2003; 14:2280.</a></li><li><a class="nounderline abstract_t">Outeda P, Huso DL, Fisher SA, et al. Polycystin signaling is required for directed endothelial cell migration and lymphatic development. Cell Rep 2014; 7:634.</a></li><li><a class="nounderline abstract_t">Boulter C, Mulroy S, Webb S, et al. Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl Acad Sci U S A 2001; 98:12174.</a></li><li><a class="nounderline abstract_t">Berbari NF, O'Connor AK, Haycraft CJ, Yoder BK. The primary cilium as a complex signaling center. Curr Biol 2009; 19:R526.</a></li><li><a class="nounderline abstract_t">Kim H, Xu H, Yao Q, et al. Ciliary membrane proteins traffic through the Golgi via a Rabep1/GGA1/Arl3-dependent mechanism. Nat Commun 2014; 5:5482.</a></li><li><a class="nounderline abstract_t">Cai Y, Fedeles SV, Dong K, et al. Altered trafficking and stability of polycystins underlie polycystic kidney disease. J Clin Invest 2014; 124:5129.</a></li><li><a class="nounderline abstract_t">Gainullin VG, Hopp K, Ward CJ, et al. Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner. J Clin Invest 2015; 125:607.</a></li><li><a class="nounderline abstract_t">Carone FA, Nakamura S, Bacallao R, et al. Impaired tubulogenesis of cyst-derived cells from autosomal dominant polycystic kidneys. Kidney Int 1995; 47:861.</a></li><li><a class="nounderline abstract_t">Ha K, Nobuhara M, Wang Q, et al. The heteromeric PC-1/PC-2 polycystin complex is activated by the PC-1 N-terminus. Elife 2020; 9.</a></li><li><a class="nounderline abstract_t">Chen XZ, Vassilev PM, Basora N, et al. Polycystin-L is a calcium-regulated cation channel permeable to calcium ions. Nature 1999; 401:383.</a></li><li><a class="nounderline abstract_t">Basora N, Nomura H, Berger UV, et al. Tissue and cellular localization of a novel polycystic kidney disease-like gene product, polycystin-L. J Am Soc Nephrol 2002; 13:293.</a></li><li><a class="nounderline abstract_t">Kleene SJ, Kleene NK. The native TRPP2-dependent channel of murine renal primary cilia. Am J Physiol Renal Physiol 2017; 312:F96.</a></li><li><a class="nounderline abstract_t">Vien TN, Wang J, Ng LCT, et al. Molecular dysregulation of ciliary polycystin-2 channels caused by variants in the TOP domain. Proc Natl Acad Sci U S A 2020; 117:10329.</a></li><li><a class="nounderline abstract_t">Bhunia AK, Piontek K, Boletta A, et al. PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 2002; 109:157.</a></li><li><a class="nounderline abstract_t">Kim E, Arnould T, Sellin L, et al. Interaction between RGS7 and polycystin. Proc Natl Acad Sci U S A 1999; 96:6371.</a></li><li><a class="nounderline abstract_t">Su Q, Hu F, Ge X, et al. Structure of the human PKD1-PKD2 complex. Science 2018; 361.</a></li><li><a class="nounderline abstract_t">Dong K, Zhang C, Tian X, et al. Renal plasticity revealed through reversal of polycystic kidney disease in mice. Nat Genet 2021; 53:1649.</a></li><li><a class="nounderline abstract_t">Grantham JJ. The etiology, pathogenesis, and treatment of autosomal dominant polycystic kidney disease: recent advances. Am J Kidney Dis 1996; 28:788.</a></li><li><a class="nounderline abstract_t">Ye M, Grant M, Sharma M, et al. Cyst fluid from human autosomal dominant polycystic kidneys promotes cyst formation and expansion by renal epithelial cells in vitro. J Am Soc Nephrol 1992; 3:984.</a></li><li><a class="nounderline abstract_t">Woo DD, Miao SY, Pelayo JC, Woolf AS. Taxol inhibits progression of congenital polycystic kidney disease. Nature 1994; 368:750.</a></li><li><a class="nounderline abstract_t">Gardner KD Jr, Glew RH, Evan AP, et al. Why renal cysts grow. Am J Physiol 1994; 266:F353.</a></li><li><a class="nounderline abstract_t">Gardner KD Jr, Burnside JS, Skipper BJ, et al. On the probability that kidneys are different in autosomal dominant polycystic disease. Kidney Int 1992; 42:1199.</a></li><li><a class="nounderline abstract_t">Grantham JJ, Ye M, Davidow C, et al. Evidence for a potent lipid secretagogue in the cyst fluids of patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 6:1242.</a></li><li><a class="nounderline abstract_t">Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354:2122.</a></li><li><a class="nounderline abstract_t">Qian F, Watnick TJ, Onuchic LF, Germino GG. The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 1996; 87:979.</a></li><li><a class="nounderline abstract_t">Brasier JL, Henske EP. Loss of the polycystic kidney disease (PKD1) region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst pathogenesis. J Clin Invest 1997; 99:194.</a></li><li><a class="nounderline abstract_t">Lu W, Peissel B, Babakhanlou H, et al. Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nat Genet 1997; 17:179.</a></li><li><a class="nounderline abstract_t">Pei Y, Watnick T, He N, et al. Somatic PKD2 mutations in individual kidney and liver cysts support a "two-hit" model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1999; 10:1524.</a></li><li><a class="nounderline abstract_t">Watnick TJ, Torres VE, Gandolph MA, et al. Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease. Mol Cell 1998; 2:247.</a></li><li><a class="nounderline abstract_t">Watnick T, He N, Wang K, et al. Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations. Nat Genet 2000; 25:143.</a></li><li><a class="nounderline abstract_t">Zhang Z, Bai H, Blumenfeld J, et al. Detection of PKD1 and PKD2 Somatic Variants in Autosomal Dominant Polycystic Kidney Cyst Epithelial Cells by Whole-Genome Sequencing. J Am Soc Nephrol 2021; 32:3114.</a></li><li><a class="nounderline abstract_t">Wu G, Markowitz GS, Li L, et al. Cardiac defects and renal failure in mice with targeted mutations in Pkd2. Nat Genet 2000; 24:75.</a></li><li><a class="nounderline abstract_t">Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ, et al. Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum Mol Genet 2004; 13:3069.</a></li><li><a class="nounderline abstract_t">Jiang ST, Chiou YY, Wang E, et al. Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1. Am J Pathol 2006; 168:205.</a></li><li><a class="nounderline abstract_t">Harris PC. What is the role of somatic mutation in autosomal dominant polycystic kidney disease? J Am Soc Nephrol 2010; 21:1073.</a></li><li><a class="nounderline abstract_t">Boca M, Distefano G, Qian F, et al. Polycystin-1 induces resistance to apoptosis through the phosphatidylinositol 3-kinase/Akt signaling pathway. J Am Soc Nephrol 2006; 17:637.</a></li><li><a class="nounderline abstract_t">Song X, Di Giovanni V, He N, et al. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum Mol Genet 2009; 18:2328.</a></li><li><a class="nounderline abstract_t">Piontek K, Menezes LF, Garcia-Gonzalez MA, et al. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med 2007; 13:1490.</a></li><li><a class="nounderline abstract_t">Torres JA, Rezaei M, Broderick C, et al. Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease. J Clin Invest 2019; 129:4506.</a></li><li><a class="nounderline abstract_t">Takakura A, Contrino L, Beck AW, Zhou J. Pkd1 inactivation induced in adulthood produces focal cystic disease. J Am Soc Nephrol 2008; 19:2351.</a></li><li><a class="nounderline abstract_t">Happé H, Leonhard WN, van der Wal A, et al. Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways. Hum Mol Genet 2009; 18:2532.</a></li><li><a class="nounderline abstract_t">Sudarikova AV, Vasileva VY, Sultanova RF, Ilatovskaya DV. Recent advances in understanding ion transport mechanisms in polycystic kidney disease. Clin Sci (Lond) 2021; 135:2521.</a></li><li><a class="nounderline abstract_t">Davidow CJ, Maser RL, Rome LA, et al. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int 1996; 50:208.</a></li><li><a class="nounderline abstract_t">Hanaoka K, Devuyst O, Schwiebert EM, et al. A role for CFTR in human autosomal dominant polycystic kidney disease. Am J Physiol 1996; 270:C389.</a></li><li><a class="nounderline abstract_t">O'Sullivan DA, Torres VE, Gabow PA, et al. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998; 32:976.</a></li><li><a class="nounderline abstract_t">Hanaoka K, Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 2000; 11:1179.</a></li><li><a class="nounderline abstract_t">Yang B, Sonawane ND, Zhao D, et al. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008; 19:1300.</a></li><li><a class="nounderline abstract_t">Grantham JJ, Ye M, Gattone VH 2nd, Sullivan LP. In vitro fluid secretion by epithelium from polycystic kidneys. J Clin Invest 1995; 95:195.</a></li><li><a class="nounderline abstract_t">Grantham JJ. Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. Kidney Int 2003; 64:1157.</a></li><li><a class="nounderline abstract_t">Belibi FA, Reif G, Wallace DP, et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004; 66:964.</a></li><li><a class="nounderline abstract_t">Torres VE. Type II calcimimetics and polycystic kidney disease: unanswered questions. J Am Soc Nephrol 2009; 20:1421.</a></li><li><a class="nounderline abstract_t">Rees S, Kittikulsuth W, Roos K, et al. Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease. J Am Soc Nephrol 2014; 25:232.</a></li><li><a class="nounderline abstract_t">Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10:363.</a></li><li><a class="nounderline abstract_t">Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367:2407.</a></li><li><a class="nounderline abstract_t">Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 2017; 377:1930.</a></li><li><a class="nounderline abstract_t">Nagao S, Nishii K, Yoshihara D, et al. Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat. Kidney Int 2008; 73:269.</a></li><li><a class="nounderline abstract_t">Torres VE, Boletta A, Chapman A, et al. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol 2010; 5:1312.</a></li><li><a class="nounderline abstract_t">Shillingford JM, Piontek KB, Germino GG, Weimbs T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 2010; 21:489.</a></li><li><a class="nounderline abstract_t">Shillingford JM, Leamon CP, Vlahov IR, Weimbs T. Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol 2012; 23:1674.</a></li><li><a class="nounderline abstract_t">Rowe I, Chiaravalli M, Mannella V, et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 2013; 19:488.</a></li><li><a class="nounderline abstract_t">Lian X, Wu X, Li Z, et al. The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease. Br J Pharmacol 2019; 176:711.</a></li><li><a class="nounderline abstract_t">Takiar V, Nishio S, Seo-Mayer P, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A 2011; 108:2462.</a></li><li><a class="nounderline abstract_t">Pastor-Soler NM, Li H, Pham J, et al. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model. Am J Physiol Renal Physiol 2022; 322:F27.</a></li><li><a class="nounderline abstract_t">Leonhard WN, Song X, Kanhai AA, et al. Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease. EBioMedicine 2019; 47:436.</a></li><li><a class="nounderline abstract_t">Perrone RD, Abebe KZ, Watnick TJ, et al. Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). Kidney Int 2021; 100:684.</a></li><li><a class="nounderline abstract_t">Brosnahan GM, Wang W, Gitomer B, et al. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Am J Kidney Dis 2022; 79:518.</a></li><li><a class="nounderline abstract_t">Warner G, Hein KZ, Nin V, et al. Food Restriction Ameliorates the Development of Polycystic Kidney Disease. J Am Soc Nephrol 2016; 27:1437.</a></li><li><a class="nounderline abstract_t">Hopp K, Ward CJ, Hommerding CJ, et al. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest 2012; 122:4257.</a></li><li><a class="nounderline abstract_t">Torres JA, Kruger SL, Broderick C, et al. Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease. Cell Metab 2019; 30:1007.</a></li><li><a class="nounderline abstract_t">Olsan EE, Mukherjee S, Wulkersdorfer B, et al. Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease. Proc Natl Acad Sci U S A 2011; 108:18067.</a></li><li><a class="nounderline abstract_t">Bello-Reuss E, Holubec K, Rajaraman S. Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int 2001; 60:37.</a></li><li><a class="nounderline abstract_t">Wei W, Popov V, Walocha JA, et al. Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study. Kidney Int 2006; 70:1261.</a></li><li><a class="nounderline abstract_t">Nichols MT, Gidey E, Matzakos T, et al. Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Hepatology 2004; 40:836.</a></li><li><a class="nounderline abstract_t">Watnick T, Germino G. From cilia to cyst. Nat Genet 2003; 34:355.</a></li><li><a class="nounderline abstract_t">Harris PC. 2008 Homer W. Smith Award: insights into the pathogenesis of polycystic kidney disease from gene discovery. J Am Soc Nephrol 2009; 20:1188.</a></li><li><a class="nounderline abstract_t">Fischer E, Legue E, Doyen A, et al. Defective planar cell polarity in polycystic kidney disease. Nat Genet 2006; 38:21.</a></li><li><a class="nounderline abstract_t">Saburi S, Hester I, Fischer E, et al. Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease. Nat Genet 2008; 40:1010.</a></li><li><a class="nounderline abstract_t">Joly D, Hummel A, Ruello A, Knebelmann B. Ciliary function of polycystins: a new model for cystogenesis. Nephrol Dial Transplant 2003; 18:1689.</a></li><li><a class="nounderline abstract_t">Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003; 33:129.</a></li><li><a class="nounderline abstract_t">DeCaen PG, Delling M, Vien TN, Clapham DE. Direct recording and molecular identification of the calcium channel of primary cilia. Nature 2013; 504:315.</a></li><li><a class="nounderline abstract_t">Pennekamp P, Karcher C, Fischer A, et al. The ion channel polycystin-2 is required for left-right axis determination in mice. Curr Biol 2002; 12:938.</a></li><li><a class="nounderline abstract_t">Ma M, Tian X, Igarashi P, et al. Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease. Nat Genet 2013; 45:1004.</a></li><li><a class="nounderline abstract_t">Pazour GJ. Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease. J Am Soc Nephrol 2004; 15:2528.</a></li><li><a class="nounderline abstract_t">Ansley SJ, Badano JL, Blacque OE, et al. Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome. Nature 2003; 425:628.</a></li><li><a class="nounderline abstract_t">Li JB, Gerdes JM, Haycraft CJ, et al. Comparative genomics identifies a flagellar and basal body proteome that includes the BBS5 human disease gene. Cell 2004; 117:541.</a></li></ol></div><div id="topicVersionRevision">Topic 1682 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1946928" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Polycystic kidney disease re-evaluated: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18832246" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical practice. Autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30135240" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11156533" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bilineal disease and trans-heterozygotes in autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7759112" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evidence for a third genetic locus for autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10193811" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Long-term follow-up of a family with autosomal dominant polycystic kidney disease type 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Is there a third gene for autosomal dominant polycystic kidney disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23760289" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35896117" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Monoallelic pathogenic ALG5 variants cause atypical polycystic kidney disease and interstitial fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24491980" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Polycystin-1: a master regulator of intersecting cystic pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27259053" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mutations in GANAB, Encoding the Glucosidase IIαSubunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28375157" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Isolated polycystic liver disease genes define effectors of polycystin-1 function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31395617" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : ALG9 Mutation Carriers Develop Kidney and Liver Cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29706351" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34890546" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2215575" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The diagnosis and prognosis of autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2890952" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Improved early diagnosis of adult polycystic kidney disease with flanking DNA markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8298643" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19443633" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Family history of renal disease severity predicts the mutated gene in ADPKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10023895" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23431072" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Type of PKD1 mutation influences renal outcome in ADPKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8004675" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7736581" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8981910" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Identification and localization of polycystin, the PKD1 gene product.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20219615" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Molecular advances in autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9773786" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A spectrum of mutations in the polycystic kidney disease-2 (PKD2) gene from eight Canadian kindreds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8650545" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15780076" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Molecular pathogenesis of ADPKD: the polycystin complex gets complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7894481" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9382094" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17582161" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17574468" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Evaluating the clinical utility of a molecular genetic test for polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22383692" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19165178" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22031115" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A missense mutation in PKD1 attenuates the severity of renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26453610" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26139440" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comprehensive PKD1 and PKD2 Mutation Analysis in Prenatal Autosomal Dominant Polycystic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569302" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison between siblings and twins supports a role for modifier genes in ADPKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15677307" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Progressive loss of renal function is an age-dependent heritable trait in type 1 autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15780078" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Modifier genes play a significant role in the phenotypic expression of PKD1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20616171" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Genetic variation of DKK3 may modify renal disease severity in ADPKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28522688" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Polycystic Kidney Disease without an Apparent Family History.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31980075" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Next-generation sequencing for detection of somatic mosaicism in autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31874800" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11140688" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12482949" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18003909" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Essential role of cleavage of Polycystin-1 at G protein-coupled receptor proteolytic site for kidney tubular structure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15545994" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18632682" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Polycystin-1 C-terminal tail associates with beta-catenin and inhibits canonical Wnt signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14711914" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16049073" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Increased activity of activator protein-1 transcription factor components ATF2, c-Jun, and c-Fos in human and mouse autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29426897" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27768895" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The Structure of the Polycystic Kidney Disease Channel PKD2 in Lipid Nanodiscs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27991905" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Structure of the polycystic kidney disease TRP channel Polycystin-2 (PC2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9171830" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : PKD1 interacts with PKD2 through a probable coiled-coil domain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9177229" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Polycystin: in vitro synthesis, in vivo tissue expression, and subcellular localization identifies a large membrane-associated protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10562308" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Polycystin-1, the PKD1 gene product, is in a complex containing E-cadherin and the catenins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12937304" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Analysis of the polycystins in aortic vascular smooth muscle cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24767998" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Polycystin signaling is required for directed endothelial cell migration and lymphatic development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11593033" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19602418" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The primary cilium as a complex signaling center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25405894" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ciliary membrane proteins traffic through the Golgi via a Rabep1/GGA1/Arl3-dependent mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25365220" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Altered trafficking and stability of polycystins underlie polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25574838" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7752585" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Impaired tubulogenesis of cyst-derived cells from autosomal dominant polycystic kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33164752" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The heteromeric PC-1/PC-2 polycystin complex is activated by the PC-1 N-terminus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10517637" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Polycystin-L is a calcium-regulated cation channel permeable to calcium ions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11805156" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Tissue and cellular localization of a novel polycystic kidney disease-like gene product, polycystin-L.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27760766" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The native TRPP2-dependent channel of murine renal primary cilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32332171" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Molecular dysregulation of ciliary polycystin-2 channels caused by variants in the TOP domain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12007403" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10339594" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Interaction between RGS7 and polycystin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30093605" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Structure of the human PKD1-PKD2 complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34635846" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Renal plasticity revealed through reversal of polycystic kidney disease in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8957030" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The etiology, pathogenesis, and treatment of autosomal dominant polycystic kidney disease: recent advances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1333294" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cyst fluid from human autosomal dominant polycystic kidneys promotes cyst formation and expansion by renal epithelial cells in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7908721" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Taxol inhibits progression of congenital polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8160782" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Why renal cysts grow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1453604" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : On the probability that kidneys are different in autosomal dominant polycystic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589292" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Evidence for a potent lipid secretagogue in the cyst fluids of patients with autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16707749" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Volume progression in polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8978603" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9005987" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Loss of the polycystic kidney disease (PKD1) region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326937" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10405208" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Somatic PKD2 mutations in individual kidney and liver cysts support a "two-hit" model of cystogenesis in type 2 autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9734362" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10835625" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34716216" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Detection of PKD1 and PKD2 Somatic Variants in Autosomal Dominant Polycystic Kidney Cyst Epithelial Cells by Whole-Genome Sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10615132" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cardiac defects and renal failure in mice with targeted mutations in Pkd2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15496422" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16400024" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20488953" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : What is the role of somatic mutation in autosomal dominant polycystic kidney disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16452497" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Polycystin-1 induces resistance to apoptosis through the phosphatidylinositol 3-kinase/Akt signaling pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19346236" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17965720" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31361604" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18776127" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Pkd1 inactivation induced in adulthood produces focal cystic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19401297" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34751394" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Recent advances in understanding ion transport mechanisms in polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8807590" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8772467" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A role for CFTR in human autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9856513" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10864573" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385427" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7814614" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : In vitro fluid secretion by epithelium from polycystic kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12969132" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327388" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19520753" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Type II calcimimetics and polycystic kidney disease: unanswered questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24158982" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14991049" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121377" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Tolvaptan in patients with autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29105594" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17943077" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20498248" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20075061" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22859856" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Folate-conjugated rapamycin slows progression of polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23524344" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30515768" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21262823" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34806449" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31473186" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34186056" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34391872" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26538633" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Food Restriction Ameliorates the Development of Polycystic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23064367" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31631001" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22025716" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422734" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Angiogenesis in autosomal-dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16883324" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15382115" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12923538" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : From cilia to cyst.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19423684" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : 2008 Homer W. Smith Award: insights into the pathogenesis of polycystic kidney disease from gene discovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16341222" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Defective planar cell polarity in polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18604206" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12937209" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Ciliary function of polycystins: a new model for cystogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12514735" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24336289" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Direct recording and molecular identification of the calcium channel of primary cilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12062060" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : The ion channel polycystin-2 is required for left-right axis determination in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23892607" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466257" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520415" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15137946" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Comparative genomics identifies a flagellar and basal body proteome that includes the BBS5 human disease gene.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
